t-AML/MDS, Chemotherapy, Radiotherapy, Children, MalignancyTherapy-related acute myeloid leukemia/myelodysplastic syndrome (t-AML/MDS) is a devastating late effect of cancer treatment. There is limited data on incidence of t-AML/MDS from India. We retrospecti...
Therapy-related AML (t-AML) is a myeloid neoplasm that evolves secondary to cytotoxic therapy (chemotherapy and/or radiotherapy) for malignant or non-malignant diseases due to DNA damage in hematopoietic progenitor cells. Approximately 5–15% of adult AML patients are reported to have t-AML [1,...
We have studied 20 children with therapy-related myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) who were 3 months to 16 years old at diagnosis of their primary neoplasm and 1 to 24 years old at diagnosis of their secondary neoplasm. The median interval from initial treatment fo...
Therapy-related myelodysplastic syndrome/acute myeloid leukemia (t-MDS/AML) is an increasingly recognized treatment complication in patients treated with radiotherapy or chemotherapy for previous hematologic malignancies or solid tumors. Distinct clinical entities have been described according to the primary tr...
TreatmentChemotherapy adverse effectsAllogeneic bone marrow transplantationMinitransplantationTherapy-related leukemia and therapy-related myelodysplasia (t-AML/MDS) are serious and increasingly frequent complications of cytotoxic chemotherapy and/or radiotherapy. Two syndromes can be distinguished, one of which ...
Younger age at diagnosis of primary malignancy and treatment with intercalating agents as well as topoisomerase II inhibitors were associated with shorter latency periods to the occurrence of t-AML. In multivariable analyses, t-AML was an adverse prognostic factor for death in complete remission but ...
In the current World Health Organization (WHO)-classification, therapy-related myelodysplastic syndromes (t-MDS) are categorized together with therapy-related acute myeloid leukemia (AML) and t-myelodysplastic/myeloproliferative neoplasms into one subgro
Therefore, efforts have been made to individualize treatment even for patients with t-AML. In this context, t-AML is no longer considered separately (with regard to treatment) in the latest European LeukemiaNet recommendations (2022 ELN) [15]. In ELN guidelines, the term “therapy-related” ...
topoisomerase II inhibitor-related type. Interindividual variability in the risk for development of t-MDS/AML suggests a rolefor genetic variation in susceptibility to genotoxic exposures. Treatment of t-MDS/AML withconventional therapy is associated with a uniformly poor prognosis, with a median ...
Although disease-related immune-suppression plays a crucial role in leukemogenesis there is great concern that therapy may further increase the risk of developing these devastating complications. lt;/spangt;lt;/pgt;lt;p class=MsoNormal style=margin: 0cm 0cm 0pt; line-height: 150%; text-align...